Single-Cell Analysis Links Immune Cells to Kidney Cancer Recurrence
Columbia University faculty present research on a previously unknown type of immune cell in kidney tumors that can predict which patients are likely to have cancer recur after surgery.
Urology & Oncology
Bladder Cancer: Therapeutic Trio Offers Potential Alternative to Radical Cystectomy
Patients with Bacillus Calmette-Guerin (BCG)-unresponsive bladder cancer remain a challenging patient population to treat. Radical cystectomy continues as the oncologic gold standard treatment in patients at high risk of recurrence after BCG failure in non-muscle-invasive bladder cancer.
The Upward Trajectory of Robotic-Assisted Radical Cystectomy
Robotic-assisted radical cystectomy has assumed its rightful place in the skill set of urologic oncologists. The application of robotics to perform radical cystectomy has been steadily increasing since its introduction nearly two decades ago.
Current Perspectives in the Treatment of Bladder Cancer
Today, there are more options for the treatment of bladder cancer than ever before. Urologic oncologists in the Department of Urology at NewYork-Presbyterian/Columbia are established experts in both robotic and laparoscopic techniques for the treatment of urologic tumors, specifically bladder, kidney, prostate, and testicular cancer.
Laparoscopic Donor Nephrectomy: Continuing Refinements in the Standard of Care
In kidney transplantation, laparoscopic donor nephrectomy is now the standard of care for living donors, a technique not widely available until the late 1990s.
Male Reproductive and Sexual Medicine
Peter J. Stahl, MD, gravitated to the subspecialty of reproductive and sexual medicine for a simple reason. This field provides an opportunity to make a big difference in someone’s life.
Center for Male Reproductive Medicine and Microsurgery
For more than three decades, the Departments of Urology at NewYork-Presbyterian have contributed greatly to the growing body of knowledge about men’s sexual and reproductive health.
Urology & Oncology
Weill Cornell Medicine Awarded SPORE Grant in Prostate Cancer
Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute to improve the detection, diagnosis, and treatment of prostate cancer.
Page1 of 2